Global private equity firm Advent International has divested its stake in Cohance Lifesciences, generating proceeds of Rs 3,094 crore. The transaction reflects strong investor confidence in India’s pharmaceutical and life sciences sector, which continues to attract both domestic and international capital. Analysts note that the exit underscores Cohance’s robust operational performance, strategic positioning, and growth trajectory. The sale is expected to enable Advent to realize returns while providing liquidity for reinvestment.